Upcycling drugs for brain-related diseases: A sustainable future for targeted drug delivery

Therapeutic Delivery

Volumn 4, Issue 4, 2013, Pages 435-438

  De Boer, Marco ^a   Visser, Corine C ^a   Gaillard, Pieter J ^a  

^a to BBB Technologies BV   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

2B 3 101; 2B 3 201; ANTINEOPLASTIC AGENT; DEXAMETHASONE; DOXORUBICIN; GLUCOCORTICOID; GLUTATHIONE; GLUTATHIONE PEGYLATED LIPOSOMAL DOXORUBICIN; GLUTATHIONE PEGYLATED LIPOSOMAL METHYLPREDNISOLONE; LIPOSOME; MACROGOL; METHYLPREDNISOLONE; PREDNISOLONE; UNCLASSIFIED DRUG;

AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; BLOOD BRAIN BARRIER; BONE DENSITY; BRAIN CANCER; BRAIN DISEASE; BRAIN METASTASIS; BRAIN TUMOR; BREAST CANCER; DIABETES MELLITUS; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG INDUSTRY; DRUG MARKETING; DRUG PENETRATION; DRUG RESEARCH; DRUG SAFETY; DRUG TARGETING; FLUID RETENTION; GASTROINTESTINAL SYMPTOM; GLIOMA; GLUCOSE INTOLERANCE; HEALTH CARE COST; HUMAN; HYPERGLYCEMIA; INFECTION; LIPOSOMAL DELIVERY; LYSOSOME STORAGE DISEASE; MOOD CHANGE; MULTIPLE SCLEROSIS; NERVOUS SYSTEM INFLAMMATION; NEUROPATHIC PAIN; PATENT; PRIORITY JOURNAL; RECURRENT CANCER; RISK BENEFIT ANALYSIS; SIDE EFFECT; SODIUM RETENTION; SUSTAINABLE DEVELOPMENT; WEIGHT GAIN;

EID: 84875956499     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.13.7     Document Type: Article

References (18)

1. Hansen J. Storms of my Grandchildren, the Truth About the Coming Climate Catastrophe and Our Last Chance to Save Humanity. Bloomsbury Press, NY, USA (2009
2. Intergovernmental Panel On Climate Change. Climate change and water, IPCC Technical Paper VI. Bates BC, Kundzewicz ZW, Wu S, Palutikof JP (Eds). IPCC Secretariat, Geneva, Switzerland, 210 (2008
3. Chung JW, Meltzer DO. Estimate of the carbon footprint of the US health care sector. JAMA 302(18), 1970-1972 (2009
4. Harrison C. Dangling from the patent cliff. Nat. Rev. Drug Discov. 12, 14-15 (2013
5. McDonough W, Braungart M. Cradle to Cradle, Remaking the Way we Make Things. North Point Press, NY, USA (2002
6. Khanna I. Drug discovery in pharmaceutical industry: Productivity challenges and trends. Drug Discov. Today 17, 1088-1102 (2012
7. Light D, Lexchin J. Pharmaceutical R&D. What do we get for all that money? BMJ 345, 22-24 (2012
8. The Neurotechnology Industry 2012 Report. Drugs, Biologics, Stem Cells, Devices and Diagnostics for the Brain and Nervous System: Market Analysis and Strategic Investment Guide of the Global Neurological Disease and Psychiatric Illness Markets. (2012
9. Gaillard P. Crossing barriers from blood-to-brain and academia-to-industry. Ther. Deliv. 1(4), 495-500 (2010
10. Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352(10), 987-996 (2005
11. De Vries NA, Beijnen JH, Boogerd W, van Tellingen O. Blood-brain barrier and chemotherapeutic treatment of brain tumors. Expert Rev. Neurother. 6(8), 1199-1209 (2006
12. Gaillard PJ, Gladdines W, Appeldoorn CCM et al. Development of glutathione pegylated liposomal doxorubicin (2B3-101) for the treatment of brain cancer. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research. IL, USA, 31 March-4 April 2012
13. O'Callaghan JP, Sriram K, Miller DB. Defining 'neuroinflammation' lessons from MPTP - And methamphetamine-induced neurotoxicity. Ann. NY Acad. Sci. 1139, 318-330 (2008
14. Rauchhaus U, Kinne RW, Pohlers D et al. Targeted delivery of liposomal dexamethasone phosphate to the spleen provides a persistent therapeutic effect in rat antigen-induced arthritis. Ann. Rheum. Dis. 68(12), 1933-1934 (2009
15. Crielaard BJ, Lammers T, Morgan ME et al. Macrophages and liposomes in inflammatory disease: Friends or foes? Int. J. Pharm. 416(2), 499-506 (2011
16. Avnir Y, Ulmansky R, Wasserman V et al. Amphipathic weak acid glucocorticoid prodrugs remote-loaded into sterically stabilized nanoliposomes evaluated in arthritic rats and in a beagle dog: A novel approach to treating autoimmune arthritis. Arthr. Rheum. 58(1), 119-129 (2008
17. Linker RA, Weller C, Luhder F et al. Liposomal glucocorticosteroids in treatment of chronic autoimmune demyelination: Long-term protective effects and enhanced efficacy of methylprednisolone formulations. Exp. Neurol. 211(2), 397-406 (2008
18. Gaillard, PJ, Appeldoorn CCM, Rip J et al. Enhanced brain delivery of liposomal methylprednisolone improved therapeutic efficacy in a model of neuroinflammation. J. Control. Release 164(3), 364-369 (2012